Short Interest in IceCure Medical Ltd (NASDAQ:ICCM) Expands By 26.9%

IceCure Medical Ltd (NASDAQ:ICCM) was the target of a significant growth in short interest in July. As of July 15th, there was short interest totalling 196,500 shares, a growth of 26.9% from the June 30th total of 154,900 shares. Approximately 0.9% of the shares of the company are sold short. Based on an average daily volume of 264,000 shares, the short-interest ratio is presently 0.7 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $3.00 target price on shares of IceCure Medical in a research report on Tuesday, July 2nd.

IceCure Medical Stock Performance

Shares of ICCM traded up $0.00 during midday trading on Tuesday, reaching $0.74. 75,590 shares of the stock were exchanged, compared to its average volume of 482,518. The business’s 50-day moving average price is $0.82 and its 200 day moving average price is $1.11. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.39 and a quick ratio of 2.88. IceCure Medical has a twelve month low of $0.52 and a twelve month high of $1.57. The company has a market capitalization of $33.76 million, a price-to-earnings ratio of -2.24 and a beta of 0.57.

IceCure Medical (NASDAQ:ICCM) last issued its quarterly earnings results on Tuesday, May 28th. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.08). The firm had revenue of $0.74 million for the quarter, compared to analysts’ expectations of $0.80 million. IceCure Medical had a negative return on equity of 101.66% and a negative net margin of 444.30%. During the same quarter in the previous year, the firm posted ($0.08) EPS. On average, sell-side analysts expect that IceCure Medical will post -0.28 EPS for the current fiscal year.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.